Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2013-01-28 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Phase II all-oral combination studies of Simeprevir, TMC647055 and IDX719 for the treatment of Hepatitis C to be initiated shortly
Regulatory Filings Classification · 95% confidence The document is titled as a 'Press Release' dated January 28, 2013, announcing a collaboration between Janssen and Idenix for the clinical development of an all-oral Hepatitis C therapy involving simeprevir, TMC647055, and IDX719. It details upcoming clinical trial phases (Phase I drug-drug interaction study, Phase II studies) and provides background information on the compounds and the disease. This content is characteristic of an announcement regarding business development, clinical progress, or partnership, rather than a formal regulatory filing like a 10-K, an earnings report (ER), or a comprehensive interim report (IR). Since it is a press release announcing business/clinical updates, it does not fit the specific categories like M&A (TAR), Capital (CAP), or Director's Dealing (DIRS). It is a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release that doesn't fit a more specific operational or financial category, although 'Report Publication Announcement' (RPA) is sometimes used for announcements, this document is announcing clinical progress and collaboration, not the publication of a formal financial report.
2013-01-28 English
Medivir announces phase III data for Simeprevir demonstrating efficacy and safety in genotype 1 hepatitis C patients
Earnings Release Classification · 99% confidence The document is titled "Press Release 20 December 2012" and announces "top-line results" from three pivotal phase III trials (QUEST-1, QUEST-2, PROMISE) regarding the efficacy and safety of the drug Simeprevir. It provides key statistical results (SVR12 rates, safety profile) and concludes with details about an upcoming conference call to discuss these results. This structure—a brief announcement highlighting key financial/operational results for a reporting period (in this case, clinical trial outcomes)—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K), an Interim Report (IR), or a transcript of a call (CT), but rather the initial public announcement of significant operational results. FY 2012
2012-12-20 English
Medivir meddelar Simeprevir fas III-resultat, som visar effekt och säkerhet i hepatit C-patienter av genotyp 1
Earnings Release Classification · 99% confidence The document is a press release dated December 20, 2012, announcing 'top-line' results from three pivotal Phase III clinical trials (QUEST-1, QUEST-2, and PROMISE) for the drug simeprevir in treating Hepatitis C. It details efficacy (SVR12 rates) and safety profiles, includes summary tables of results, and mentions that final analyses are ongoing and complete results will be presented at future scientific conferences. It also announces a conference call for the same day. This content strongly aligns with an Earnings Release (ER) or a major clinical/business update announcement, which typically precedes a formal quarterly or annual report. Since it focuses purely on announcing key financial/clinical results (efficacy data) rather than being a comprehensive periodic report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification, even though the content is clinical trial results rather than traditional quarterly revenue/profit figures. It is a primary announcement of performance/results. FY 2012
2012-12-20 Swedish
Medivir meddelar att del två av den interferonfria fas II-studien med Simeprevir och sofosbuvir för behandling av hepatit C inletts
Legal Proceedings Report Classification · 99% confidence The document is a press release dated December 13, 2012, announcing that Medivir has initiated the second part of a Phase II clinical trial for Simeprevir in combination with Sofosbuvir for Hepatitis C treatment. This type of announcement, detailing clinical trial progress, study design, and future presentation plans, is a standard corporate update. It is not a full Annual Report (10-K), a formal Audit Report (AR), a Dividend Notice (DIV), or a formal Earnings Release (ER) which typically focuses on financial metrics. Since it is a specific announcement about ongoing research and development activities, it best fits the category for general corporate or regulatory updates that aren't covered by the more specific financial or governance codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release detailing clinical trial progress, although it could also be argued as a type of Investor Information. However, RNS serves as the general regulatory announcement category for non-standard filings. Given the nature of the content (a press release about clinical trial initiation), RNS is the best fit among the provided codes as a general regulatory/corporate announcement.
2012-12-13 Swedish
Medivir announces initiation of the second cohort of the interferon-free phase II study combining Simeprevir and sofosbuvir for hepatitis C treatment
Legal Proceedings Report Classification · 99% confidence The document is a press release dated December 13, 2012, announcing the initiation of the second cohort of a Phase II clinical study combining Simeprevir and sofosbuvir for hepatitis C treatment. It details study design, patient cohorts, and provides background information on the drug and the disease. This type of announcement, detailing clinical trial progress and scientific updates, is characteristic of an Investor Presentation (IP) or a general regulatory/investor communication. Since it is a detailed update on clinical development and strategy, 'Investor Presentation' (IP) is the most fitting category, as it conveys detailed information intended for investors about the company's pipeline progress, which often overlaps with content found in formal presentations. It is not an Earnings Release (ER) as it focuses on clinical trials, not financial results. It is not a Call Transcript (CT) as it is a written release. It is not a formal regulatory filing like 10-K or IR. Given the content focuses heavily on R&D progress and pipeline assets, IP is the best fit.
2012-12-13 English
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period 1 January – 30 September 2012. It contains comprehensive financial statements, including income statements, balance sheet summaries, and detailed management commentary on business performance, R&D projects, and future outlook. It is not an announcement of a report, but the report itself, containing substantive financial data. 9M 2012
2012-11-20 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.